Edition:
United States

CytomX Therapeutics Inc (CTMX.O)

CTMX.O on Nasdaq

17.79USD
24 Mar 2017
Change (% chg)

$0.37 (+2.12%)
Prev Close
$17.42
Open
$17.50
Day's High
$18.48
Day's Low
$17.40
Volume
303,598
Avg. Vol
186,443
52-wk High
$20.02
52-wk Low
$9.10

CTMX.O

Chart for CTMX.O

About

CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics... (more)

Overall

Beta: --
Market Cap(Mil.): $650.55
Shares Outstanding(Mil.): 36.57
Dividend: --
Yield (%): --

Financials

  CTMX.O Industry Sector
P/E (TTM): -- 47.98 29.94
EPS (TTM): -1.63 -- --
ROI: -34.16 -2.56 13.01
ROE: -57.59 5.14 14.16

BRIEF-Cytomx Therapeutics announces proposed resale of up to 10.9 mln shares by selling stockholders

* Cytomx Therapeutics Inc - files for proposed resale or other disposition of up to 10.9 million shares of co by the selling stockholders - SEC filing Source text for Eikon: Further company coverage:

Mar 09 2017

BRIEF-Cytomx announces full-year 2016 financial results

* Cytomx announces full-year 2016 financial results Source text for Eikon: Further company coverage:

Mar 02 2017

BRIEF-Cytomx announces the first patient treated in phase 1/2 proclaim-072 trial

* Cytomx announces the first patient treated in phase 1/2 proclaim-072 trial Source text for Eikon: Further company coverage:

Feb 02 2017

BRIEF-Cytomx Therapeutics files for mixed shelf of upto $250 mln - SEC filing

* Cytomx Therapeutics Inc - files for mixed shelf of upto $250 million - SEC filing Source text: (http://bit.ly/2fmn5Jx) Further company coverage:

Nov 03 2016

BRIEF-Cytomx therapeutics announces Q3 2016 results; provides pipeline update

* Qtrly loss per share $0.40; co expects "its existing capital resources will be sufficient to fund operations through 2018"

Nov 03 2016

More From Around the Web

Earnings vs. Estimates